Summary & Overview
HCPCS J2650: Prednisolone Acetate Injection, Up to 1 ml
HCPCS Level II code J2650 denotes an injection of prednisolone acetate, up to 1 ml, a commonly used ophthalmic corticosteroid for intraocular or periocular anti-inflammatory therapy. This code matters nationally because it captures billing for a routine therapeutic procedure in eye care, with implications for outpatient reimbursement, utilization monitoring, and formulary management. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what the code represents clinically and operationally, how major payers typically approach coverage and billing for injectable ophthalmic corticosteroids, and what benchmarks and policy considerations are relevant for outpatient ophthalmology services. The publication provides context on service settings where J2650 is used, common billing practices for single-dose ocular injections, and areas where policy updates or payer guidance can affect claims handling. Data not available in the input for specific payer policies, fee schedules, or ICD-10 linkage is noted where applicable. The focus is national in scope and oriented toward helping billing managers, revenue cycle professionals, and clinical administrators understand the role and billing context of HCPCS Level II code J2650 within outpatient ophthalmic care.
Billing Code Overview
HCPCS Level II code J2650 describes an injection of prednisolone acetate, up to 1 ml. This code represents a single-dose ocular corticosteroid injection typically used for anti-inflammatory treatment in ophthalmic care. The service type is an injection (ophthalmic corticosteroid), and the typical site of service is an ophthalmology clinic, ambulatory surgery center, or outpatient department where ocular injections are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an ophthalmology clinic with acute anterior uveitis or an exacerbation of chronic allergic conjunctivitis causing marked ocular inflammation, pain, photophobia, and decreased vision. After history and slit-lamp examination confirm significant anterior segment inflammation and topical therapy is insufficient or impractical, the ophthalmologist administers an ocular corticosteroid injection. The billed item J2650 documents the medication product, prednisolone acetate, up to 1 mL, used for periocular or intraocular corticosteroid delivery.
The clinical workflow: the patient is consented for injection, allergy and medication history are reviewed, topical anesthesia and aseptic preparation are performed, and the clinician administers the injection (sub-Tenon or subconjunctival or intraocular route depending on indication). Post-procedure vital signs and a brief observation period follow; topical antibiotics or pressure checks may be performed, and follow-up is scheduled for intraocular pressure monitoring and inflammation reassessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or resources exceed typical for injection (extensive difficulty, additional time). |